Bioresorbable Nonwoven Patches as Taxane Delivery Systems for Prostate Cancer Treatment.
cabazitaxel
docetaxel
polymeric drug delivery systems
prostate cancer therapy
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 Dec 2022
17 Dec 2022
Historique:
received:
28
10
2022
revised:
01
12
2022
accepted:
14
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Prostate cancer is the second most common cancer in males. In the case of locally advanced prostate cancer radical prostatectomy is one of the first-line therapy. However, recurrence after resection of the tumor can appear. Drug-eluting bioresorbable implants acting locally in the area of the tumor or the resection margins, that reduce the risk of recurrence would be advantageous. Electrospinning offers many benefits in terms of local delivery so fiber-forming polyesters and polyestercarbonates which are suitable to be drug-loaded were used in the study to obtain CTX or DTX-loaded electrospun patches for local delivery. After a fast verification step, patches based on the blend of poly(glycolide-ε-caprolactone) and poly(lactide-glycolide) as well as patches obtained with poly(lactide-glycolide- ε-caprolactone) were chosen for long-term study. After three months, 60% of the drug was released from (PGCL/PLGA) + CTX and it was selected for final, anticancer activity analysis with the use of PC-3 and DU145 cells to establish its therapeutic potential. CTX-loaded patches reduced cell growth to 53% and 31% respectively, as compared to drug-free patches. Extracts from drug-free patches showed excellent biocompatibility with the PC-3 cell line. Cabazitaxel-loaded bioresorbable patches are a promising drug delivery system for prostate cancer therapy.
Identifiants
pubmed: 36559328
pii: pharmaceutics14122835
doi: 10.3390/pharmaceutics14122835
pmc: PMC9786168
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : 2020/04/X/NZ7/00016
Organisme : Medical University of Silesia
ID : PCN-1-104/N/1/F
Références
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Sep 25;:e1854
pubmed: 36161272
Theranostics. 2017 Apr 10;7(7):1806-1819
pubmed: 28638469
Biomacromolecules. 2007 Nov;8(11):3661-7
pubmed: 17941671
Curr Oncol. 2007 Oct;14(5):189-94
pubmed: 17938702
Drug Deliv. 2016 Oct;23(8):2677-2685
pubmed: 26171813
Biomaterials. 2000 Dec;21(23):2335-46
pubmed: 11055281
J Urol. 2006 Sep;176(3):991-5
pubmed: 16890678
J Control Release. 2021 Jun 10;334:463-484
pubmed: 33781809
Dtsch Arztebl Int. 2021 Apr 02;118(Forthcoming):
pubmed: 33549154
Int J Pharm. 2012 Sep 15;434(1-2):115-21
pubmed: 22659126
J Biomater Sci Polym Ed. 2019 May;30(7):547-560
pubmed: 30897033
Artif Cells Nanomed Biotechnol. 2015;43(4):263-9
pubmed: 24621011
Int J Pharm. 2021 Jun 1;602:120596
pubmed: 33857588
Nanomedicine (Lond). 2017 Sep;12(17):2083-2095
pubmed: 28805551
J Histochem Cytochem. 1998 Aug;46(8):895-900
pubmed: 9671440
Med Eng Phys. 2011 Mar;33(2):148-63
pubmed: 21075668
Biomacromolecules. 2005 Jan-Feb;6(1):489-97
pubmed: 15638557
Biomacromolecules. 2005 Jan-Feb;6(1):483-8
pubmed: 15638556